ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
PO Box 28,
South Australia 5007
North Terrace House,
19 North Terrace,
Hackney, SA, 5069
1300 128 339
Closed over Christmas
(reopened 1 February 2017)
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Fibromyalgia patients who stopped long-term milnacipran therapy exhibited greater response loss
Monday 26 August 2013
Patients with fibromyalgia who had received milnacipran therapy for an average of 3 years had a greater loss of therapeutic response when switched to placebo compared with those who continued treatment, according to recent study results.
Researchers studied patients with fibromyalgia who had received 50 mg/day to 200 mg/day milnacipran for up to 3.25 years in a long-term, open-label lead-in study. Prior treatment included a maximum of 15 months of milnacipran at 100 mg/day or 200 mg/day, resulting in up to 4.5 years of milnacipran exposure.
Three hundred forty patients completed a 4-week open-label period, in which they received the same milnacipran dosage as the lead-in study. One hundred fifty patients who received a minimum of 100/mg day milnacipran and achieved at least 50% improvement in visual analog scale (VAS) for pain were classified as responders. They were randomly assigned to continue milnacipran (n=100) or placebo (n=50) in a 12-week, double blind withdrawal period.
VAS pain score to less than 30% reduction from pre-milnacipran exposure or worsening of fibromyalgia that would require alternative therapy were defined as loss of therapeutic response (LTR). Placebo patients experienced a shorter time to LTR (median, 56 days) compared with patients who maintained treatment (primary analysis; HR=0.44; 95% CI, 0.27-0.71). Less than 50% of the patients on milnacipran lost response by the end of study, making LTR incalculable.
Among the patients who remained on milnacipran, 81% maintained clinically meaningful pain response, defined as better than 30% improvement from pre-milnacipran exposure, compared with 58% of patients switched to placebo (sensitivity analysis II; P<.001).
Fifty-eight percent of placebo-treated and 47% of milnacipran-treated patients experienced one or more treatment-emergent adverse events, none considered serious.
“In patients who had received milnacipran for an average of 3 years … loss of therapeutic response upon discontinuation of treatment provides evidence of long-term efficacy of this medication for the management of fibromyalgia,” the researchers concluded.
Disclosure: See the study for a full list of relevant financial disclosures.
The above originally appeared here.
blog comments powered by Disqus